A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Corporate Information We originally incorporated as Micromed Laboratories, Inc. in 1999 under the laws of the State of California. We changed our name to Oculus Innovative Sciences, Inc. in 2001. In December 2006 we reincorporated under the laws of the State of Delaware, and in December 2016 we changed our name to Sonoma Pharmaceuticals, Inc. Our principal executive offices are located at 5445 Conestoga Court, Suite 150, Boulder, Colorado 80301. We have two active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A. de C.V., and Sonoma Pharmaceuticals Netherlands, B.V. Our fiscal year end is March 31. Our corporate telephone number is (800) 759-9305. Our websites are www.sonomapharma.com and www.sonomapharma.eu. The websites and any information contained therein or connected thereto is not intended to be incorporated into this report.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 18M | 14M | 13M | 13M | 13M | 19M |
| Net Income | -3.4M | -3.5M | - | -5.2M | -5.1M | -4.0M |
| EPS | $-1.95 | $-2.79 | $-10.63 | $-5.49 | $-20.58 | $-39.40 |
| Free Cash Flow | -3.7M | -168K | -2.4M | -6.4M | -4.4M | -3.6M |
| ROIC | -250.9% | -78.4% | - | -64.6% | -54.2% | -59.2% |
| Gross Margin | 38.2% | 38.2% | 37.3% | 33.7% | 31.6% | 35.2% |
| Debt/Equity | 0.00 | 0.05 | 0.05 | 0.05 | 0.16 | 0.36 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -2.8M | -3.7M | -4.7M | -4.6M | -5.9M | -3.4M |
| Operating Margin | -15.6% | -26.0% | -36.9% | -34.4% | -46.6% | -18.5% |
| ROE | -98.2% | -65.5% | - | -64.6% | -58.5% | -71.9% |
| Shares Outstanding | 2M | 1M | 2M | 1M | 0M | 0M |
Sonoma Pharmaceuticals, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 35.2%.
Sonoma Pharmaceuticals, Inc. (SNOA) has a 5-year average return on invested capital (ROIC) of -64.1%. This is below average and may indicate limited pricing power.
Sonoma Pharmaceuticals, Inc. (SNOA) has a market capitalization of $4M. It is classified as a small-cap stock.
Sonoma Pharmaceuticals, Inc. (SNOA) does not currently pay a regular dividend.
Sonoma Pharmaceuticals, Inc. (SNOA) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Sonoma Pharmaceuticals, Inc. (SNOA) reported annual revenue of $14 million in its most recent fiscal year, based on SEC EDGAR filings.
Sonoma Pharmaceuticals, Inc. (SNOA) has a net profit margin of -24.2%. The company is currently unprofitable.
Sonoma Pharmaceuticals, Inc. (SNOA) generated $-168 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Sonoma Pharmaceuticals, Inc. (SNOA) has a debt-to-equity ratio of 0.05. This indicates a conservatively financed balance sheet.
Sonoma Pharmaceuticals, Inc. (SNOA) reported earnings per share (EPS) of $-2.79 in its most recent fiscal year.
Sonoma Pharmaceuticals, Inc. (SNOA) has a return on equity (ROE) of -65.5%. A negative ROE may indicate losses or negative equity.
Sonoma Pharmaceuticals, Inc. (SNOA) has a 5-year average gross margin of 35.2%. This indicates decent pricing power.
The Ledger Terminal provides 15 years of financial data for Sonoma Pharmaceuticals, Inc. (SNOA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Sonoma Pharmaceuticals, Inc. (SNOA) has a book value per share of $3.56, based on its most recent annual SEC filing.